Major Depressive Disorder (MDD)Depressive DisordersObsessive-Compulsive Disorder (OCD)Substance Use Disorders (SUD)Palliative & End-of-Life DistressAnxiety DisordersPsilocybin

DARK Classics in Chemical Neuroscience: Psilocybin

This literature review (2018) looks back at the research that has been done with psilocybin, and the promise that it holds in current clinical trials.

Authors

  • Geiger, H. A.
  • Wurst, M. G.
  • Daniels, R. N.

Published

ACS Chemical Neuroscience
meta Study

Abstract

Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.

Available with Blossom Pro

Research Summary of 'DARK Classics in Chemical Neuroscience: Psilocybin'

Introduction

Geiger and colleagues introduce psilocybin as the principal psychoactive alkaloid found in a range of ‘‘magic mushrooms’’ and place it in the broader chemical family of indolealkylamine compounds related to serotonin, melatonin and N,N-dimethyltryptamine. The text summarises basic physico-chemical contrasts between psilocybin and its active metabolite psilocin (for example, psilocybin: six hydrogen bond acceptors, three hydrogen bond donors, logP 0.03; psilocin: three acceptors, two donors, logP 1.32), and notes that psilocybin acts as a prodrug that is rapidly dephosphorylated to the more lipophilic psilocin, which can cross the blood–brain barrier to produce psychoactive effects. Beyond chemistry, the introduction sketches psilocybin’s historical arc: its isolation and synthesis by Albert Hofmann in the late 1950s, clinical and recreational rise in the 1960s, scheduling and resultant research hiatus after 1970, and recent re-emergence of clinical interest. The authors frame the review to cover synthesis and biosynthesis, metabolism, pharmacology, adverse reactions, legal/manufacturing constraints and the emerging clinical evidence for disorders such as obsessive–compulsive disorder, substance use disorders and depression in both terminal illness and treatment-resistant cases.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (26)

Papers cited by this study that are also in Blossom

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

423 cited
Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)

345 cited
Psychedelics not linked to mental health problems or suicidal behavior: A population study.

Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)

Show all 26 references
Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Potential Therapeutic Effects of Psilocybin

Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin

Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)

202 cited
Can psychedelics have a role in psychiatry once again?

Sessa, B. · British Journal of Psychiatry (2018)

96 cited
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Psilocybin in end of life care: Implications for further research

Summergrad, P. · Journal of Psychopharmacology (2021)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited

Cited By (10)

Papers in Blossom that reference this study

Methyl transfer in psilocybin biosynthesis

Hudspeth, J., Rogge, K., Dörner, S. et al. · Nature Communications (2024)

Effects of hallucinogenic drugs on the human heart

Neumann, J., Dhein, S., Kirchhefer, U. et al. · Frontiers in Pharmacology (2024)

Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use

Barnett, B. S., Sweat, N. W., Hendricks, P. S. · Drug Science Policy and Law (2023)

4 cited
Therapeutic effect of psilocybin in addiction: A systematic review

van der Meer, P. B., Fuentes, J. J., Kaptein, A. A. et al. · Frontiers in Psychiatry (2023)

Serotonergic Psychedelics in Neural Plasticity

Torregrossa, M. M., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)

Discriminative Stimulus Effects of Substituted Tryptamines in Rats

Gatch, M. B., Hoch, A., Carbonaro, T. M. · ACS Pharmacology and Translational Science (2020)

8 cited
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine

Palamar, J. J., Acosta, P. · Human Psychopharmacology (2020)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.